Rosuvastatin Calcium Tablet
Product Images NDC 68788-4078

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Rosuvastatin Calcium (NDC 68788-4078). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Rosuvastatin Tablets 5mg (Rosuvastatin Tablets 5mg 90s Bottle Label)

Rosuvastatin Tablets 5mg (Rosuvastatin Tablets 5mg 90s Bottle Label)
This text is from a pharmaceutical product label for Rosuvastatin Tablets 5mg, which is a generic version of Crestor. The tablets contain Rosuvastatin calcium equivalent to rosuvastatin 5mg. The packaging size, expiration date, and lot/batch number are provided. The manufacturer is Umedica Laboratories Pvt. Ltd. It emphasizes caution regarding the transfer of the drug to individuals other than the prescribed patient. The tablets are round, pink, and imprinted with K5. Instructions in Spanish are also included. The label features information on quantity, insurance, lot/batch numbers, and product codes for different tablet versions.*
FDA Label Image

Figure_1_time_jupiter (Rosuvastatin Tablets Figure 1)

Figure_1_time_jupiter (Rosuvastatin Tablets Figure 1)
This text provides statistical information related to a study or trial, showing a hazard ratio (HR) of 0.56 with a 95% confidence interval (CI) ranging from 0.46 to 0.69, indicating a significant difference. It also mentions a P-value less than 0.001, further supporting the statistical significance. The table seems to display cumulative incidence percentages and numerical data "at risk" for two groups labeled as "RSV" and "Placebo". The specific details of the study or trial under evaluation are not available.*
FDA Label Image

Figure_2-major_jupiter (Rosuvastatin Tablets Figure 2)

Figure_2-major_jupiter (Rosuvastatin Tablets Figure 2)
This is a comparison of the efficacy of Rosuvastatin 20 mg versus Placebo 20 mg in reducing cardiovascular events. The study involved 8901 participants and reported data on primary endpoint (MCE), cardiovascular death, nonfatal stroke, nonfatal myocardial infarction (MI), and arterial revascularization. Rosuvastatin showed a significant reduction in primary endpoint events (Hazard Ratio 0.56, P<0.001) compared to Placebo. Additionally, Rosuvastatin demonstrated lower rates of cardiovascular death, stroke, MI, and arterial revascularization compared to Placebo. The event rates per 1000-patient years were provided for each endpoint to assess the efficacy of the two treatments.*
FDA Label Image

Figure_3_percent_dyslipidemia (Rosuvastatin Tablets Figure 3)

Figure_3_percent_dyslipidemia (Rosuvastatin Tablets Figure 3)
This text seems to list the dosage (mg) of different cholesterol-lowering medications: CRESTOR, Atorvastatin, Simvastatin, and Pravastatin, along with the percent change in LDL-C levels for each dose.*
FDA Label Image
Logo (Rosuvastatin Tablets Logo)
FDA Label Image

Logo1 (Rosuvastatin Tablets Logo2)

Logo1 (Rosuvastatin Tablets Logo2)
FDA Label Image

Structural_formula (Rosuvastatin Tablets Structure)

Structural_formula (Rosuvastatin Tablets Structure)
Not available.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.